Journal
ONCOLOGIST
Volume 23, Issue 9, Pages 1079-1082Publisher
WILEY
DOI: 10.1634/theoncologist.2017-0674
Keywords
-
Categories
Funding
- Bristol-Myers Squibb (Princeton, NJ)
- Ono Pharmaceutical Company Ltd. (Osaka, Japan)
- Bristol-Myers Squibb
Ask authors/readers for more resources
Nivolumab significantly improved overall survival (OS) vs investigator's choice (IC) of chemotherapy at the primary analysis of randomized, open-label, phase 3 CheckMate 141 in patients with recurrent or metastatic (R/M) squamous cell carcinoma of the head and neck (SCCHN). Here, we report that OS benefit with nivolumab was maintained at a minimum follow-up of 11.4 months. Further, OS benefit with nivolumab vs IC was also noted among patients who received first-line treatment for R/M SCCHN after progressing on platinum therapy for locally advanced disease in the adjuvant or primary (i.e., with radiation) setting.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available